Milford company Rentschler Biopharma says they are closing their UK facility and shifting their focus away from cell and gene therapy. The Worcester Business Journal reports Rentschler cites a drop in demand for the genetics work and a rise in demand for biologics which is the focus of the Milford site which just underwent a major expansion.
